Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced its participation in TD Cowen's 45th Annual Health Care Conference. The company's management will engage in a fireside chat scheduled for March 5, 2025, at 7:30 a.m. PT / 10:30 a.m. ET / 3:30 p.m. GMT.
The event will be accessible via audio webcast through the Investors section of Jazz Pharmaceuticals' website, with recordings available for 30 days post-event. Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for patients with serious diseases, particularly in areas with therapeutic options.
The company maintains a diverse portfolio of marketed medicines, specializing in sleep disorders and epilepsy treatments, along with an expanding cancer treatment portfolio. Their research and development efforts span both oncology and neuroscience, with operations and facilities across multiple countries, headquartered in Dublin, Ireland.
Jazz Pharmaceuticals (Nasdaq: JAZZ) ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. Il management dell'azienda parteciperà a una chiacchierata informale programmata per il 5 marzo 2025, alle 7:30 PT / 10:30 ET / 15:30 GMT.
L'evento sarà accessibile tramite un webcast audio nella sezione Investitori del sito web di Jazz Pharmaceuticals, con registrazioni disponibili per 30 giorni dopo l'evento. Jazz Pharmaceuticals è una compagnia biofarmaceutica globale focalizzata nello sviluppo di farmaci che cambiano la vita per i pazienti con malattie gravi, in particolare in aree con opzioni terapeutiche limitate.
L'azienda mantiene un portafoglio diversificato di farmaci commercializzati, specializzandosi in disturbi del sonno e trattamenti per l'epilessia, insieme a un portafoglio in espansione di trattamenti per il cancro. I loro sforzi di ricerca e sviluppo si estendono sia all'oncologia che alle neuroscienze, con operazioni e strutture in diversi paesi, con sede a Dublino, Irlanda.
Jazz Pharmaceuticals (Nasdaq: JAZZ) ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. La dirección de la compañía participará en una charla informal programada para el 5 de marzo de 2025, a las 7:30 a.m. PT / 10:30 a.m. ET / 3:30 p.m. GMT.
El evento será accesible a través de una transmisión de audio en la sección de Inversores del sitio web de Jazz Pharmaceuticals, con grabaciones disponibles durante 30 días después del evento. Jazz Pharmaceuticals es una compañía biofarmacéutica global enfocada en desarrollar medicamentos que cambian la vida para pacientes con enfermedades graves, particularmente en áreas con opciones terapéuticas limitadas.
La empresa mantiene un portafolio diverso de medicamentos comercializados, especializándose en trastornos del sueño y tratamientos para la epilepsia, junto con un portafolio en expansión de tratamientos contra el cáncer. Sus esfuerzos de investigación y desarrollo abarcan tanto la oncología como las neurociencias, con operaciones e instalaciones en varios países, con sede en Dublín, Irlanda.
재즈 제약 (Nasdaq: JAZZ)는 TD Cowen의 제45회 연례 건강 관리 회의에 참여한다고 발표했습니다. 회사의 경영진은 2025년 3월 5일 오전 7시 30분 PT / 오전 10시 30분 ET / 오후 3시 30분 GMT에 예정된 화상 대화에 참여할 것입니다.
이 행사는 재즈 제약 웹사이트의 투자자 섹션을 통해 오디오 웹캐스트로 접근할 수 있으며, 행사 후 30일 동안 녹음된 내용이 제공됩니다. 재즈 제약은 심각한 질병을 앓고 있는 환자들을 위한 삶을 변화시키는 의약품 개발에 집중하는 글로벌 바이오 제약 회사입니다. 특히 치료 옵션이 제한된 분야에 중점을 둡니다.
회사는 수면 장애 및 간질 치료를 전문으로 하는 다양한 상용 의약품 포트폴리오를 유지하고 있으며, 암 치료 포트폴리오도 확장하고 있습니다. 그들의 연구 및 개발 노력은 종양학과 신경 과학 모두에 걸쳐 있으며, 여러 국가에서 운영 및 시설을 두고 있으며, 본사는 아일랜드 더블린에 있습니다.
Jazz Pharmaceuticals (Nasdaq: JAZZ) a annoncé sa participation à la 45ème Conférence Annuelle sur la Santé de TD Cowen. La direction de l'entreprise participera à une discussion informelle prévue pour le 5 mars 2025, à 7h30 PT / 10h30 ET / 15h30 GMT.
L'événement sera accessible via un webinaire audio dans la section Investisseurs du site web de Jazz Pharmaceuticals, avec des enregistrements disponibles pendant 30 jours après l'événement. Jazz Pharmaceuticals est une entreprise biopharmaceutique mondiale axée sur le développement de médicaments qui changent la vie pour les patients atteints de maladies graves, notamment dans des domaines avec des options thérapeutiques limitées.
L'entreprise maintient un portefeuille diversifié de médicaments commercialisés, se spécialisant dans les troubles du sommeil et les traitements de l'épilepsie, ainsi qu'un portefeuille en expansion de traitements contre le cancer. Leurs efforts de recherche et développement couvrent à la fois l'oncologie et les neurosciences, avec des opérations et des installations dans plusieurs pays, dont le siège est à Dublin, en Irlande.
Jazz Pharmaceuticals (Nasdaq: JAZZ) hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben. Das Management des Unternehmens wird an einem informellen Gespräch teilnehmen, das für den 5. März 2025 um 7:30 Uhr PT / 10:30 Uhr ET / 15:30 Uhr GMT geplant ist.
Die Veranstaltung wird über ein Audio-Webcast im Bereich Investoren der Website von Jazz Pharmaceuticals zugänglich sein, mit Aufzeichnungen, die 30 Tage nach der Veranstaltung verfügbar sind. Jazz Pharmaceuticals ist ein globales Biopharma-Unternehmen, das sich auf die Entwicklung lebensverändernder Medikamente für Patienten mit schweren Krankheiten konzentriert, insbesondere in Bereichen mit begrenzten therapeutischen Optionen.
Das Unternehmen verfügt über ein vielfältiges Portfolio an vermarkteten Medikamenten, das sich auf Schlafstörungen und Epilepsiebehandlungen spezialisiert hat, sowie über ein sich ausweitendes Portfolio an Krebsbehandlungen. Ihre Forschungs- und Entwicklungsaktivitäten erstrecken sich sowohl auf Onkologie als auch auf Neurowissenschaften, mit Betrieben und Einrichtungen in mehreren Ländern, mit Sitz in Dublin, Irland.
- None.
- None.
An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in
Contacts:
Investors:
Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-td-cowens-45th-annual-health-care-conference-302381787.html
SOURCE Jazz Pharmaceuticals plc
FAQ
When is Jazz Pharmaceuticals (JAZZ) presenting at TD Cowen's Healthcare Conference 2025?
How long will the JAZZ conference webcast be available for replay?
What are the main therapeutic areas for Jazz Pharmaceuticals (JAZZ)?
Where can investors access the JAZZ TD Cowen conference webcast?
What is Jazz Pharmaceuticals' (JAZZ) geographical presence?
